✦ LIBER ✦

Combination chemotherapy and high-dose cyclophosphamide intensification for poor prognosis breast cancer. A southwest oncology group study

✍ Scribed by Georgiana K. Ellis; Stephanie Green; Susan Schulman; Bill L. Tranum; Ronald S. Goldberg; Robert B. Livingston

Publisher: John Wiley and Sons
Year: 1989
Tongue: English
Weight: 625 KB
Volume: 64
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19891215)64:12<2409::aid-cncr2820641202>3.0.co;2-t

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combination chemotherapy and adriamycin

Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study

✍ B. Hoogstraten; S. L. George; B. Samal; S. E. Rivkin; J. J. Costanzi; J. D. Bonn 📂 Article 📅 1976 🏛 John Wiley and Sons 🌐 English ⚖ 595 KB

Short-term chemotherapy of poor-prognosi

Short-term chemotherapy of poor-prognosis metastatic breast cancer with three non-cross resistant chemotherapy regimens. A southwest oncology group study

✍ Frederick R. Ahmann; Reginald Pugh 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 546 KB

A Southwest Oncology Group pilot study was designed to evaluate a brief, 4.5-month induction course of chemotherapy with three presumably non-cross resistant regimens in poor-prognosis metastatic breast cancer. Sixty-three patients were treated with doxorubicin, cyclophosphamide, plus vincristine on

Adriamycin in combination for the treatm

Adriamycin in combination for the treatment of breast cancer. A southwest oncology group study

✍ Dr. B. Tranum; B. Hoogstraten; A. Kennedy; C. B. Vaughn; B. Samal; T. Thigpen; S 📂 Article 📅 1978 🏛 John Wiley and Sons 🌐 English ⚖ 431 KB 👁 2 views

Patients with advanced breast cancer who had not previously received chemotherapy were treated on a three-arm prospective study: adriamycin day 1 plus 5-FU on day 1 and 8 (AF), adriamycin day 1 , plus 5-FU day 1 and 8 , and cyclophosphamide day 1 (AFC), and adriamycin day 1 plus 5-FU day 1 and 8 , c

Dose-response and dose-survival advantag

Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer a southwest oncology group study

✍ Michael K. Samson; Saul E. Rivkin; Stephen E. Jones; John J. Costanzi; Albert F. 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 565 KB

Combination chemotherapy (CMFVP) versus

Combination chemotherapy (CMFVP) versus L-phenylalanine mustard (L-PAM) for operable breast cancer with positive axillary nodes. A southwest oncology group study

✍ Harold Glucksberg; Saul E. Rivkin; Shelley Rasmussen; Bill Tranum; Nazli Gad-el- 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 970 KB

The Southwest Oncology Group in a prospective randomized study compared one year of adjuvant combination chemotherapy with continuous CMFVP to two years of intermittent L-PAM in women with operable breast cancer with histologically positive axillary lymph nodes. In fully evaluable patients with a 42

Adjuvant chemotherapy with cyclophospham

Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes : 20-year results of a Southwest Oncology Group Study

✍ Saul E. Rivkin; Stephanie J. Green; Danika Lew; John J. Costanzi; John W. Athens 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 1 views

## Abstract ## BACKGROUND Adjuvant combination chemotherapy with cyclophosphamide, methotrexate, and 5‐fluorouracil plus vincristine and prednisone (CMFVP) was compared with single‐agent L‐phenylalanine mustard (L‐PAM) for the treatment of patients with axillary lymph node positive primary breast